Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)
Clinical trial NCT03059303 · TERMINATED
Trial details
- NCT number
- NCT03059303
- Sponsor
- Janssen Research & Development, LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-20
- Primary completion
- 2017-04-24
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.